Monopar Therapeutics Inc SEC Filings

Monopar Therapeutics (MNPR) filed its Q3 2025 10-Q. The company ended September 30, 2025 with cash and cash equivalents of $127.7 million and investments of $16.0 million, lifting total assets to $144.2 million from $60.3 million at year-end 2024. Net loss was $3.44 million for the quarter and $8.52 million year-to-date, driven by R&D of $2.59 million and G&A of $1.50 million in Q3. Interest income contributed $655,473 in Q3 and $2.03 million year-to-date.

Monopar completed a September 2025 capital raise comprising 1,034,433 common shares at $67.67 and pre-funded warrants for 960,542 shares at $67.669, generating approximately $126.9 million in net proceeds after underwriting discounts. The company used $35.0 million to repurchase 550,229 shares at $63.6098 from Tactic Pharma. Shares outstanding were 6,662,930 at September 30, 2025 and 6,682,584 as of October 31, 2025. Management stated it has sufficient funds to meet obligations at least through December 31, 2027.

Monopar Therapeutics (MNPR) furnished an 8‑K under Regulation FD announcing it issued a press release about presenting new data and analyses from the Phase 2 ALXN1840‑WD‑204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting 2025. The press release is included as Exhibit 99.1 and incorporated by reference.

Monopar Therapeutics (MNPR) insider filing: Andrew Cittadine, the company's Chief Operating Officer and a director, reported equity activity dated 09/30/2025. He received 4,327 shares upon vesting and settlement of restricted stock units. To satisfy tax withholding on the vesting, 1,896 shares were surrendered at an indicated price of $81.67 per share.

After these transactions the filing shows beneficial ownership figures reported on the form: 50,185 shares following the acquisition line and 48,289 shares following the withholding line; the form also lists 38,674 restricted stock units/RSU-related shares held following the reported transactions. The form is executed by attorney-in-fact Quan Vu on 10/02/2025.

Monopar Therapeutics (MNPR) director and CEO Dr. Robinson Chandler reported insider transactions on Form 4 showing restricted stock unit vesting and resulting share movements on 09/30/2025. He received 8,726 shares upon vesting and settlement of RSUs and had 2,646 shares withheld to satisfy withholding taxes, leaving 82,198 shares reported as directly owned after the transactions. The filing also discloses 272,026 shares held by Tactic Pharma LLC, over which Dr. Robinson may be deemed to share voting and dispositive power; he expressly disclaims beneficial ownership of those shares except to the extent of his pecuniary interest. Transactions are tied to multiple RSU grants made in 2022, 2023 and 2025 with scheduled vesting through December 31, 2028.

Monopar Therapeutics (MNPR) insiders reported a significant sale of common stock by an affiliated investor group on 09/24/2025. Tactic Pharma LLC sold 550,229 shares at a reported price of $63.6098 per share, leaving beneficial ownership of 272,026 shares following the transaction. The Form 4 is filed on behalf of Tactic and its managers—Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran—who collectively have voting control over the disclosed shares but disclaim ownership except for any pecuniary interest. Chandler D. Robinson remains subject to Section 16 reporting as CEO.

Amendment No. 2 to a Schedule 13D reports ownership changes by Tactic Pharma LLC and certain related persons in Monopar Therapeutics (MNPR) common stock. The filing states there are 6,611,661 shares outstanding after an Offering. Tactic Pharma agreed to sell 550,229 shares back to the issuer at $63.6098 per share, the same price as the Offering (net of underwriting fees), conditioned on the Offering closing. After giving effect to this transaction, several reporting persons (other than Chandler Robinson and Michael Brown) ceased to beneficially own more than 5% of the outstanding common stock. The filing also discloses a prior pro rata distribution of shares by TacticGem LLC and a mutual lock-up among Tactic Pharma and Gem Pharmecuticals until December 31, 2025, with a one-time waiver to permit the transaction described above.

Monopar Therapeutics entered into an underwriting agreement to sell 1,034,433 shares of common stock at $67.67 per share and pre-funded warrants to purchase 960,542 shares at $67.669 per pre-funded warrant, with immediate exercisability and ownership caps tied to a 9.99% threshold (adjustable to 19.99% with notice). The offering is being made from a shelf registration declared effective September 9, 2025, and is expected to close on September 25, 2025. The company also agreed to repurchase 550,229 shares from existing significant stockholder Tactic Pharma at $63.6098 per share; Chandler D. Robinson, the CEO, is a managing member of Tactic Pharma. After giving effect to the repurchase, net proceeds are expected to be approximately $91.9 million, before estimated offering expenses. A peer-reviewed letter about the company’s investigational therapy ALXN1840 was published in the Journal of Hepatology and disclosed via press release.

Monopar Therapeutics reported that it presented new long-term neurological efficacy and safety data for its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease at the 150th American Neurological Association Annual Meeting held on September 14-15, 2025. The company furnished a press release, a poster presentation, and an oral presentation as Exhibits 99.1, 99.2, and 99.3 to the report and incorporated them by reference. The filing announces the dissemination of these materials but does not include detailed efficacy or safety results within the 8-K text itself. The disclosure is intended to satisfy Regulation FD requirements by making the presentations and release publicly available.